China’s brain-computer interface industry is racing ahead
Source: TechCrunch
China’s BCI Industry Is Gaining Momentum
While Elon Musk’s Neuralink likes to say it’s pioneering brain‑computer interfaces (BCIs), China’s BCI sector is already moving from research to scale.
Why the Shift Now?
- Policy support – Provinces such as Sichuan, Hubei, and Zhejiang have set official medical‑service pricing for BCI procedures, paving the way for inclusion in the national health‑insurance system.
- Clinical trials – More hospitals are running BCI studies, expanding the evidence base for both implantable and non‑invasive devices.
- Investor interest – Venture capital is flowing into startups that can commercialize the technology.
The Entrepreneurs Behind the Push
Phoenix Peng has founded two BCI companies:
| Company | Focus | Role |
|---|---|---|
| NeuroXess | Implantable BCI devices | Co‑founder |
| Gestala | Non‑invasive ultrasound BCI | Founder & CEO |
Peng’s confidence stems from concrete actions on the ground, not just hype.
“I have always maintained that neuroscience and AI are two sides of the same coin. They are destined for deep integration, realizing direct high‑bandwidth connections between the human brain and AI. BCI will serve as the ultimate bridge between carbon‑based and silicon‑based intelligence. While this may sound distant, it represents an unimaginably vast market in the future.”
Looking Ahead
Peng envisions BCI technology moving beyond medical treatment to human augmentation—enhancing cognition, perception, and interaction with AI systems. If policy, clinical validation, and capital continue to align, China could become a global leader in both therapeutic and consumer‑grade brain‑computer interfaces.
Four Factors Driving BCI in China
Source: TechCrunch interview with Peng (June 9 2026, Boston, MA)
1. Strong Policy Support
- Cross‑department collaboration aligns technical standards and medical reimbursement.
- August 2025: China’s industry ministry and six other agencies released a national BCI roadmap that:
- Sets major technical milestones for 2027.
- Establishes common industry standards.
- Targets a full supply chain by 2030.
- December 2025 (Shenzhen BCI & HCI Expo): Announcement of an ¥11.6 billion (≈ $165 M) brain‑science fund to back BCI companies from research through commercialization.
2. Vast Clinical Resources
- Large patient pools and lower research costs accelerate trials.
- National health insurance enables rapid commercialization once the state approves a device, unlike the U.S. where each private insurer must approve coverage after FDA clearance.
- First fully implanted, wireless BCI trial (the world’s second) was completed in China, allowing a paralyzed patient to control devices without external hardware (CGTN, Dec 2025).
3. Mature Industrial Manufacturing
- China’s ecosystem spans semiconductors, AI, and medical hardware, supporting fast R&D and prototyping.
4. Strategic Investment
- Both state‑led funds and private capital are surging under national initiatives.
Notable Recent Deals
| Company (Location) | Deal / Milestone | Amount | Date |
|---|---|---|---|
| StairMed Technology (Shanghai) | Series B funding round | $48 M (≈ ¥350 M) | Feb 2025 |
| BrainCo (Hangzhou) | Hong Kong IPO filing (quiet) after raising $287 M (≈ ¥2 B) | $287 M (¥2 B) | Jan 2026 |
| Gestala (Beijing) | Angel round talks (company launched Jan 2026) | – | 2026 (ongoing) |
Leading Chinese BCI Players
- NeuroXess
- Neuracle
- NeuralMatrix
- BrainCo
- Bo Rui Kang Tech
- Aoyi Tech
- Brainland Tech
- Zhiran Medical
These firms cover a spectrum from implantable flexible interfaces to non‑invasive brain‑computer technologies.
Market Outlook
- 2025: Expected market size > $530 M (≈ ¥3.8 B), up from ¥3.2 B in 2024.
- 2040 Projection: ¥120 B (≈ $16.5 B) according to industry forecasts.
“In traditional electrical BCIs, Chinese firms have achieved clinical progress in motor and language decoding, spinal‑cord reconstruction, and stroke rehabilitation, with over 50 flexible implantable BCI clinical trials completed by mid‑2025,” – Peng
References
- National BCI Roadmap (Gov.cn, Aug 2025)
- Shenzhen BCI & HCI Expo announcement (CGTN, Dec 2025)
- StairMed Series B funding (Yahoo Finance)
- BrainCo IPO filing (Bloomberg)
- Gestala website
- China BCI market forecast (Global Times, 2025)
- Long‑term market projection (China Briefing)
BCI Types
Brain‑computer interfaces (BCIs) fall into two broad categories, each with distinct trade‑offs between signal fidelity and user convenience.
| Category | Typical Devices | Signal Modality | Advantages | Limitations |
|---|---|---|---|---|
| Invasive | NeuroXess, Neuralink | Electrophysiological (micro‑electrodes implanted in cortex) | • Neuron‑level resolution • High bandwidth, low latency | • Requires brain surgery • Infection & long‑term biocompatibility risks |
| Non‑invasive | NeuroSky, BrainCo | Electroencephalography (EEG) via headsets/headbands | • No surgery – easy to adopt • Lower cost & regulatory burden | • Signals are attenuated by skull • Coarser spatial resolution |
Key point: Most users prefer non‑invasive solutions because they avoid the risks and stigma associated with brain implants.
Emerging Approaches
Researchers and startups are expanding the BCI toolbox with methods that sit between—or go beyond—the two classic categories:
| Modality | Companies / Projects | Target Applications | Status |
|---|---|---|---|
| Ultrasound | Merge Labs (OpenAI‑backed), Gestala | Chronic pain, stroke rehabilitation, depression | Early‑stage clinical trials; Gestala expects first‑gen launch Q3 2026 |
| Magnetoencephalography (MEG) | Various academic consortia | High‑resolution brain mapping | Prototype / research phase |
| Transcranial Magnetic Stimulation (TMS) | NeuroTech, others | Neuromodulation for mood disorders | FDA‑cleared for some indications |
| Optical (fNIRS) | LightWave, OptiBrain | Cognitive monitoring, neurofeedback | Pilot studies |
| Hybrid BCIs (EEG + EMG + eye‑tracking, etc.) | Multimodal Labs | Enhanced control for assistive tech | Proof‑of‑concept demos |
These modalities aim to improve signal quality while preserving the non‑invasive user experience, thereby widening commercial scalability.
Investment Landscape
| Investor | Portfolio Company | Focus | Notable Insight |
|---|---|---|---|
| HongShan Capital (formerly Sequoia China) | Zhiran Medical (founded 2022) | Long‑term implant performance – flexible, high‑throughput electrodes | Emphasizes reducing inflammation and signal loss from rigid implants |
| Merge Labs (OpenAI‑backed) | Own ultrasound‑BCI platform | Non‑invasive treatment of chronic pain, stroke, depression | Early trials show a single session can cut pain scores by ≈ 50 %, lasting 1–2 weeks |
| Gestala | Ultrasound‑based BCI for pain & mood disorders | Rapid‑deployment, non‑invasive therapy | Plans first‑generation product release Q3 2026 |
| Individual Angels / VCs | Various EEG headset startups | Consumer‑grade neurofeedback, gaming, wellness | Face “high cost” and technical barriers despite market interest |
“Some technologies may look cutting‑edge but are far from practical application,” wrote Yang Yunxia, partner at HongShan Capital, in a recent blog post. “Others appear commercially viable, yet they confront high costs or significant technical hurdles.”
—Yunxia’s blog post
Investment decisions ultimately hinge on whether a technology can be turned into a sustainable business: scalable manufacturing, regulatory clearance, and a clear path to market adoption.
Takeaways
- Invasive BCIs deliver the highest fidelity but are limited by surgical risk and patient acceptance.
- Non‑invasive EEG headsets are safe and easy to use but sacrifice resolution.
- Emerging modalities (ultrasound, MEG, TMS, optical, hybrid) strive to bridge the gap, offering better signals without surgery.
- Commercial viability depends on balancing performance, cost, regulatory pathway, and user willingness to adopt.
These dynamics shape where founders, investors, and researchers focus their efforts in the rapidly evolving BCI ecosystem.
The Years Ahead
Over the next five years, industry insiders expect China’s BCI regulations to align more closely with international standards, with a particular focus on regulatory approval and data sovereignty. Global frameworks developed by the International Electrotechnical Commission (IEC), the International Organization for Standardization (ISO), and guidance from the U.S. Food and Drug Administration (FDA) are expected to serve as key reference points.
- IEC – Brain‑Computer Interface standards
- ISO – ISO Committee on BCI
- FDA – Regulatory guidance for neurotechnology
Anticipated Regulatory Shifts
- Invasive devices – Stricter oversight and more rigorous safety requirements.
- Data generated by BCI devices – Enhanced controls to protect data sovereignty.
- Non‑invasive technologies – Easing of approval pathways to encourage innovation.
Ethical Considerations
China plans to strengthen ethical oversight for brain‑implanted or brain‑manipulating devices by:
- Reinforcing informed‑consent requirements.
- Broadening ethics review beyond strictly medical contexts.
- Moving toward unified technical standards for clinical evaluation.
For a deeper dive into the ethical challenges, see the article on BCI ethics.